Published in J Clin Cell Immunol on December 10, 2015
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | NCT01174121
Tremelimumab With Chemoembolization or Ablation for Liver Cancer | NCT01853618
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | NCT01218867
Autologous Natural Killer T Cells Infusion for the Treatment of Cancer | NCT01801852
CIK Treatment for HCC Patient Underwent Radical Resection | NCT01749865
In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | NCT01923233
A Study of DC-CIK to Treat Hepatocellular Carcinoma | NCT01821482
Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells (ICAR) | NCT00562666
DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma | NCT02487017
Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model. J Hepatol (2016) 0.77
Smoc2 potentiates proliferation of hepatocellular carcinoma cells via promotion of cell cycle progression. World J Gastroenterol (2016) 0.75
Mouse IP-10 Gene Delivered by Folate-modified Chitosan Nanoparticles and Dendritic/tumor Cells Fusion Vaccine Effectively Inhibit the Growth of Hepatocellular Carcinoma in Mice. Theranostics (2017) 0.75
Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer. J Clin Cell Immunol (2016) 0.75
Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L. J Hepatocell Carcinoma (2017) 0.75
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
The biology of NKT cells. Annu Rev Immunol (2007) 14.43
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol (2006) 10.21
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
NKT cells: what's in a name? Nat Rev Immunol (2004) 7.84
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
A new member of the immunoglobulin superfamily--CTLA-4. Nature (1987) 5.10
Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet (2000) 4.60
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med (1992) 3.77
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer (2013) 2.87
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol (2015) 2.18
The role of NKT cells in tumor immunity. Adv Cancer Res (2008) 2.05
Natural killer cells and cancer. Adv Cancer Res (2003) 1.99
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol (2004) 1.87
Hepatocellular carcinoma - United States, 2001-2006. MMWR Morb Mortal Wkly Rep (2010) 1.74
In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood (2008) 1.67
Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother (2005) 1.65
NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol (2007) 1.61
Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut (2011) 1.56
NKT cells and tumor immunity--a double-edged sword. Nat Immunol (2000) 1.53
A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res (2006) 1.48
NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol (2008) 1.46
Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol (2005) 1.41
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med (2012) 1.40
Strategies for immunotherapy of cancer. Adv Immunol (2000) 1.36
A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis (2008) 1.32
Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology (2006) 1.28
Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol (2004) 1.25
The contrasting roles of NKT cells in tumor immunity. Curr Mol Med (2009) 1.24
T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res (2003) 1.24
Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother (2008) 1.22
Cancer prevention by vaccination against hepatitis B. Recent Results Cancer Res (2009) 1.20
Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother (2005) 1.19
Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol (2000) 1.17
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology (2014) 1.16
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer (2010) 1.15
Dendritic cells in cancer immunotherapy clinical trials: are we making progress? Front Immunol (2013) 1.14
Chemoimmunotherapy. Cancer J (2010) 1.13
Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol (2015) 1.11
Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother (1998) 1.11
Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother (2013) 1.11
Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol (2013) 1.09
Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol (2002) 1.09
Natural killer cell cytotoxicity: how do they pull the trigger? Immunology (2009) 1.06
Potential of immunotherapy for hepatocellular carcinoma. J Hepatol (2010) 1.06
The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res (2015) 1.04
A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. Cancer Immunol Immunother (2008) 1.03
Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology (2013) 1.03
Cancer immunology and immunotherapy. Realizing the promise. Introduction. Science (2015) 1.00
Immunotherapeutic approaches to hepatocellular carcinoma treatment. Liver Cancer (2012) 1.00
Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy. Chin J Cancer (2010) 1.00
Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol (2014) 0.99
Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin Exp Immunol (2007) 0.97
Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study. Chin J Cancer (2010) 0.97
Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother (2013) 0.96
The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol Res (2015) 0.96
Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology (2012) 0.93
Subsets of human natural killer cells and their regulatory effects. Immunology (2014) 0.93
Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol. Cytotherapy (2012) 0.92
Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment. J Immunother (2014) 0.90
Immune Checkpoint Blockade in Cancer Therapy: The 2015 Lasker-DeBakey Clinical Medical Research Award. JAMA (2015) 0.88
Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. World J Hepatol (2015) 0.88
Cancer immunotherapy. Curr Opin Immunol (2013) 0.87
NKT cell-TCR expression activates conventional T cells in vivo, but is largely dispensable for mature NKT cell biology. PLoS Biol (2013) 0.87
Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma. Cell Transplant (2012) 0.86
Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. J Cancer Res Clin Oncol (2012) 0.83
Chimeric antigen receptor T cells for cancer immunotherapy. J Clin Oncol (2015) 0.83
Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era? Expert Rev Clin Immunol (2015) 0.83
[Clinical study of autologous cytokine induced killer cells combined with IL-2 for therapy of elderly patients with B-cell malignant lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (2010) 0.82
Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition. Oncotarget (2015) 0.82
A clinical study evaluating dendritic and cytokine-induced killer cells combined with concurrent radiochemotherapy for stage IIIB non-small cell lung cancer. Genet Mol Res (2015) 0.81
Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer (2015) 0.80
Pembrolizumab superior to ipilimumab in melanoma. Cancer Discov (2015) 0.80
Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives. Immunotherapy (2015) 0.79
Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer. World J Gastroenterol (2013) 0.79
Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes. Chin Med J (Engl) (1997) 0.78
Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic? Dig Dis (2015) 0.77
The need for natural killer T cells. Nat Med (2005) 0.77